Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India

ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens

First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China

Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.

Strides flagship facility in Bangalore receives USFDA inspection closure

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.

Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine

The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability

Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency

First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals

Bluestem Biosciences files 24 patent applications

At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals